150 related articles for article (PubMed ID: 26312753)
1. Different Mechanisms of Regulation of the Warburg Effect in Lymphoblastoid and Burkitt Lymphoma Cells.
Mushtaq M; Darekar S; Klein G; Kashuba E
PLoS One; 2015; 10(8):e0136142. PubMed ID: 26312753
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
3. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
4. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
5. c-Myc inhibition negatively impacts lymphoma growth.
Gomez-Curet I; Perkins RS; Bennett R; Feidler KL; Dunn SP; Krueger LJ
J Pediatr Surg; 2006 Jan; 41(1):207-11; discussion 207-11. PubMed ID: 16410134
[TBL] [Abstract][Full Text] [Related]
6. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
7. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
8. Expression of class I major histocompatibility complex antigens in Epstein-Barr virus-carrying lymphoblastoid cell lines and Burkitt lymphoma cells.
Jilg W; Voltz R; Markert-Hahn C; Mairhofer H; Münz I; Wolf H
Cancer Res; 1991 Jan; 51(1):27-32. PubMed ID: 1899042
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis in Burkitt lymphoma cells is driven by c-myc.
Milner AE; Grand RJ; Waters CM; Gregory CD
Oncogene; 1993 Dec; 8(12):3385-91. PubMed ID: 8247541
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
11. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
12. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
13. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
15. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
Kluiver J; Haralambieva E; de Jong D; Blokzijl T; Jacobs S; Kroesen BJ; Poppema S; van den Berg A
Genes Chromosomes Cancer; 2006 Feb; 45(2):147-53. PubMed ID: 16235244
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus reactivation induces MYC-IGH spatial proximity and t(8;14) in B cells.
Sall FB; Shmakova A; Karpukhina A; Tsfasman T; Lomov N; Canoy RJ; Boutboul D; Oksenhendler E; Toure AO; Lipinski M; Wiels J; Germini D; Vassetzky Y
J Med Virol; 2023 Mar; 95(3):e28633. PubMed ID: 36866703
[TBL] [Abstract][Full Text] [Related]
17. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
18. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
19. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Tani A; Tatsumi E; Nakamura F; Kumagai S; Kosaka Y; Sano K; Nakamura H; Amakawa R; Ohno H
Leukemia; 1996 Oct; 10(10):1592-603. PubMed ID: 8847894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
